An evaluation of the FDA Responder Endpoint for IBS‐C clinical trials: analysis of data from linaclotide Phase 3 clinical trialsJ MacDougall, Anthony J Lembo, M Currie et al.|Neurogastroenterology & Motility|2013Cited by 30
Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS‐CMichael Camilleri, Jeffrey M. Johnston, Anthony Lembo et al.|United European Gastroenterology Journal|2014Cited by 17
Psychometric validation of symptom severity measures in irritable bowel syndrome with constipationValerie Williams, J. Martin Johnston, J MacDougall et al.|Alimentary Pharmacology & Therapeutics|2014Cited by 8
Comparison of anchor-based methods for estimating thresholds of meaningful within-patient change using simulated PROMIS PF 20a data under various joint distribution characteristic conditionsShanshan Qin, Lori McLeod, Lauren Nelson et al.|Quality of Life Research|2022Cited by 7
Quantitative challenges facing patient-centered outcomes researchWen-Hung Chen, Sheri Fehnel, Lori McLeod et al.|Expert Review of Pharmacoeconomics & Outcomes Research|2014Cited by 5